Trial ID or NCT#

NCT03607422

Status

RECRUITING

Purpose

The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate to severe AD who are candidates for systemic therapy.

Official Title

A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis

Eligibility Criteria

Ages Eligible for Study: 12 Years to 75 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Justin M Ko, MD, MBA
Dermatologist, Melanoma specialist, Cutaneous oncology specialist, Hair loss specialist, Psoriasis specialist
Clinical Associate Professor, Dermatology

Contact us to find out if this trial is right for you.

CONTACT

SPECTRUM